BlueWillow Receives FDA Clearance to Begin Phase 1 Study of its Intranasal Anthrax Vaccine


The Phase 1 clinical study is expected to begin enrollment this year and is being funded by the US National Institute of Allergy and Infectious Diseases (NIAID), an institute within the US National Institutes of Health (NIH).

Content Information

Content Author: 
unknown
Content Source: 
Iosco County Herald
Content Type: 
News